Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions... | December 25, 2022

Related Keywords

Guangzhou ,Guangdong ,China ,Shanghai ,United States ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Canada ,San Francisco ,California ,Chinese ,Sheng Yao ,Junshi Bioscience ,Marek Ciszewski ,Jodi Sievers ,Junshi Biosciences ,Theresa Lavallee ,Coherus Biosciences ,Zhi Li ,Development Officer ,Institute Of Microbiology ,Ir Team ,Coherus Biosciences Inc ,Chinese Academy Of Science ,Drug Administration ,Nasdaq ,Exchange Commission ,Vp Corporate Communications ,Pr Team ,Globenewswire Inc ,Shanghai Junshi Biosciences Co Ltd ,Biologics License Application ,Prescription Drug User ,Senior Vice President ,Both Coherus ,Coheru Chief Development ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Emergency Use Authorizations ,Private Securities Litigation Reform Act ,Coheru Annual Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Fda ,Gas ,Teen ,Nable ,O ,Travel ,Conduct ,The ,Equired ,Bite ,Inspection ,Resulting ,N ,Delayed ,Action ,La ,Junshi ,Iosciences ,End ,Coherus ,Fire ,Actively ,Ngaged ,Ngoing Chrs Us19249h1032 ,